Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas

Journal of Endocrinology

Volumn 216, Issue 2, 2013, Pages 125-133

  Micali, S ^a   Maggisano, V ^b   Cesinaro, A ^a   Celano, M ^b   Territo, A ^a   Bonetti, L Reggiani ^a   Sponziello, M ^c   Migaldi, M ^a   Navarra, M ^d,e   Bianchi, G ^a   Filetti, S ^c   Russo, D ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Pharmaco Biological Department   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Embryonal carcinoma; Seminoma; Sodium iodide symporter; Testicular tumors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; FORSKOLIN; IODIDE; MEVINOLIN; RADIOACTIVE IODINE; RAPAMYCIN; SODIUM IODIDE SYMPORTER; VALPROIC ACID; VORINOSTAT; COTRANSPORTER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL MEMBRANE; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE CONTROL; EMBRYONAL CARCINOMA; EMBRYONAL TESTICULAR CARCINOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; LEYDIG CELL; LEYDIG CELL TUMOR; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEMINOMA; TESTIS CARCINOMA; TESTIS TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; REVIEW; TUMOR CELL LINE;

CARCINOMA, EMBRYONAL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RETROSPECTIVE STUDIES; SEMINOMA; SYMPORTERS; TESTICULAR NEOPLASMS;

MLCS; MLOWN;

EID: 84874787422     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0495     Document Type: Article

References (28)

1. Arturi F, Russo D, Giuffrida D, Schlumberger M & Filetti S 2000 Sodium- iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. European Journal of Endocrinology 143 623-627.
2. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germá JR, Capellá G, Villanueva A et al. 2009 Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clinical Cancer Research 15 3384-3395.
3. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E et al. 2008 Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocrine-Related Cancer 15 499-510.
4. Chi P, Allis CD & Wang GG 2010 Covalent histone modifications -miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews. Cancer 10 457-459.
5. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS & Carrasco N 2003 The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Reviews 24 48-77.
6. Eble JN, Sauter G, Epstein JI & Sesterhenn IA 2004 The Word Health Organization Classification of Tumours. Pathology and Genetics of the tumours of the urinary system and male genital organs. Eds WD Travis, E Brambilla, HK Müller-Hermelink & CC Harris. Lyon, France: IARC Press.
7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL & Trotti A. Eds 2010 In AJCC Cancer Staging Manual. 7th Edition, New York, NY, USA: Springer
8. Fröhlich E, Brossart P & Wahl R 2009 Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. European Journal of Nuclear Medicine and Molecular Imaging 26 780-790.
9. Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, Eisenhut M, Peschke P & Altmann A 2003 Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Therapy 10 774-780.
10. Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R& Harrington K 2010 The biology of the sodium iodide symporter and its potential for targeted gene delivery. Current Cancer Drug Targets 10 242-267.
11. Kogai T, Taki K & Brent GA 2006 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocrine-Related Cancer 13 797-826.
12. Krege S, Souchon R & Schmoll HJ 2001 Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumours: result of an updated conference on evidence-based medicine. European Urology 40 373-391.
13. Liu Z & Xing M 2012 Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. PLoS ONE 7 e31729.
14. Looijenga LH 2011 Spermatocytic seminoma: toward further understanding of pathogenesis. Journal of Pathology 224 431-433.
15. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, Filetti S, Bianchi G & Russo D 2010 Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology 75 773-778.
16. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T et al. 2005 Effects of histone acetylation on NIS promoter and expression of thyroid-specific transcription factors. Endocrinology 146 3967-3974.
17. Renier C, Yao C, Goris M, GhoshM, Katznelson L, Nowles K, Gambhir SS & Wapnir I 2009 Endogenous NIS expression in triple-negative breast cancers. Annals of Surgical Oncology 16 962-968.
18. Riesco-Eizaguirre G & Santisteban P 2006 A perspective view of sodium iodide symporter research and its clinical implications. European Journal of Endocrinology 155 495-512.
19. Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggisano V, Paoli D, Verrienti A, Costante G, Lenzi A et al. 2011a Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine 40 35-40.
20. Russo D, Damante G, Puxeddu E, Durante C & Filetti S 2011b Epigenetics of thyroid cancer and novel therapeutic targets. Journal of Molecular Endocrinology 46 R73-R81.
21. Schlumberger M, Lacroix L, Russo D, Filetti S & Bidart JM 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nature Clinical Practice. Endocrinology & Metabolism 3 263-269.
22. Schrader M, Kempkensteffen C, Christoph F, Hinz S, Weikert S, Lein M, Krause H, Stephan C, Jung K, Hoepfner M et al. 2009 Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options. Oncology 76 77-84.
23. Sonpavide S, Hutson TE & Roth BJ 2007Management of recurrent testicular germ cell tumors. Oncologist 12 51-61.
24. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A et al. 2010 Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Hormone and Metabolic Research 43 22-25.
25. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohán O & Carrasco N 2003 Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. Journal of Clinical Endocrinology and Metabolism 88 1880-1888.
26. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M & von der Maase H 2002 Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. Journal of Clinical Oncology 20 4448-4452.
27. Weiss SJ, Philp NJ & Grollman EF 1984 Iodine transport in a continuous line of cultured 23 cells from rat thyroid. Endocrinology 114 1090-1098.
28. Winter C & Albers P 2011 Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nature Reviews. Endocrinology 7 43-53.